Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting

Core Insights - Pacira BioSciences announced findings from two real-world studies demonstrating the economic benefits of EXPAREL in total knee arthroplasty (TKA) and spinal fusion, showing lower total costs of care compared to traditional analgesics [1][2] Study Findings - The studies included propensity score-matched cohorts evaluating outcomes on surgery day and through 30 days of follow-up in commercial and Medicare Advantage populations, revealing lower total costs and reduced healthcare resource utilization with EXPAREL [2] - In the spinal fusion study, the reductions in costs were primarily attributed to a shorter length of hospital stay for patients treated with EXPAREL [2] Specific Results from TKA Study - In the TKA study, EXPAREL was associated with significantly lower total costs compared to ropivacaine, with reductions of $409 in the commercial cohort and $1,359 in the Medicare Advantage cohort, both with P<0.001 [3] - The index procedure costs were also lower for EXPAREL, with reductions of $328 and $781 for commercial and Medicare Advantage cohorts respectively, both with P<0.0001 [3] - Additional findings included reduced home health utilization and lower inpatient admissions in the commercial population, with P<0.05 for all [3] Specific Results from Spinal Fusion Study - In the spinal fusion study, patients treated with EXPAREL had significantly lower mean total costs of $5,993.17 compared to non-LB analgesia, with P<0.05 [4] - The reduction in total medical costs was $6,001.19, also with P<0.05, and there were decreases in outpatient costs [4] - Patients treated with EXPAREL experienced a shorter length of stay by 1.83 days, with P<0.0001, and no differences in emergency department visits or inpatient readmissions [5] Company Commitment - Pacira is dedicated to advancing the economic understanding of postsurgical pain management through real-world evidence, emphasizing the value of non-opioid approaches like EXPAREL [3] - The findings support the role of EXPAREL in multimodal pain management strategies, aiming to improve patient outcomes and reduce economic barriers to access [3] Upcoming Presentations - Pacira will present these findings at the Orthopaedic Research Society (ORS) 2026 Annual Meeting, highlighting the economic advantages of EXPAREL in orthopedic procedures [1][3]